Shopping Cart
- Remove All
Your shopping cart is currently empty
EGFR/HER2-IN-11 (compound 20), an orally active dual inhibitor targeting human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR), demonstrates IC50 values of 7.7 nM and 22 nM, respectively. This compound shows strong antitumor efficacy, specifically inhibiting the proliferation of BT-474 cancer cells with a GI50 of 601 nM [1].

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 25 mg | $1,520 | 8-10 weeks | |
| 50 mg | $1,980 | 8-10 weeks | |
| 100 mg | $2,500 | 8-10 weeks |
| Description | EGFR/HER2-IN-11 (compound 20), an orally active dual inhibitor targeting human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR), demonstrates IC50 values of 7.7 nM and 22 nM, respectively. This compound shows strong antitumor efficacy, specifically inhibiting the proliferation of BT-474 cancer cells with a GI50 of 601 nM [1]. |
| In vivo | EGFR/HER2-IN-11, administered orally at a dosage of 10 mg/kg, exhibits a metabolic stability of 59 μL/min/mg and an AUC (0-8 h) of 2.476 μg·h/mL in BALB/c mice [1]. |
| Molecular Weight | 491.89 |
| Formula | C23H21ClF3N5O2 |
| Cas No. | 1346176-20-2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.